These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 10367673)

  • 1. Molecular pathology in the preclinical development of biopharmaceuticals.
    Gillett NA; Chan CM
    Toxicol Pathol; 1999; 27(1):48-52. PubMed ID: 10367673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New techniques in gene product analysis.
    DeLellis RA; Wolfe HJ
    Arch Pathol Lab Med; 1987 Jul; 111(7):620-7. PubMed ID: 3300593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow cytometry in the preclinical development of biopharmaceuticals.
    Gossett KA; Narayanan PK; Williams DM; Gore ER; Herzyk DJ; Hart TK; Sellers TS
    Toxicol Pathol; 1999; 27(1):32-7. PubMed ID: 10367670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The integration of molecular diagnostics with therapeutics. Implications for drug development and pathology practice.
    Ross JS; Ginsburg GS
    Am J Clin Pathol; 2003 Jan; 119(1):26-36. PubMed ID: 12520694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue and cell imaging in situ: potential for applications in pathology and endoscopy.
    Scoazec JY
    Gut; 2003 Jun; 52 Suppl 4(Suppl 4):iv1-6. PubMed ID: 12746261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of pathology in the identification of drug-induced hepatic toxicity.
    Cullen JM; Miller RT
    Expert Opin Drug Metab Toxicol; 2006 Apr; 2(2):241-7. PubMed ID: 16866610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the toxicologic pathologist in the biopharmaceutical industry.
    van Tongeren S; Fagerland JA; Conner MW; Diegel K; Donnelly K; Grubor B; Lopez-Martinez A; Bolliger AP; Sharma A; Tannehill-Gregg S; Turner PV; Wancket LM
    Int J Toxicol; 2011 Oct; 30(5):568-82. PubMed ID: 21878555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the toxicologic pathologist in the preclinical safety evaluation of biotechnology-derived pharmaceuticals.
    Pilling AM
    Toxicol Pathol; 1999; 27(6):678-88. PubMed ID: 10588549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
    Lebrec H; Narayanan P; Nims R
    J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interpreting and Integrating Clinical and Anatomic Pathology Results.
    Ramaiah L; Hinrichs MJ; Skuba EV; Iverson WO; Ennulat D
    Toxicol Pathol; 2017 Jan; 45(1):223-237. PubMed ID: 27879439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HTS technologies in biopharmaceutical discovery.
    Wu G; Doberstein SK
    Drug Discov Today; 2006 Aug; 11(15-16):718-24. PubMed ID: 16846799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices.
    Morford LL; Bowman CJ; Blanset DL; Bøgh IB; Chellman GJ; Halpern WG; Weinbauer GF; Coogan TP
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):359-80. PubMed ID: 21770023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. If cells could talk. The application of new techniques to cytopathology.
    Abati A; Fetsch P; Filie A
    Clin Lab Med; 1998 Sep; 18(3):561-83. PubMed ID: 9742383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thirty years of preclinical safety evaluation of biopharmaceuticals: Did scientific progress lead to appropriate regulatory guidance?
    Kooijman M; van Meer PJ; Moors EH; Schellekens H
    Expert Opin Drug Saf; 2012 Sep; 11(5):797-801. PubMed ID: 22861668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals.
    Martin PL; Breslin W; Rocca M; Wright D; Cavagnaro J
    Birth Defects Res B Dev Reprod Toxicol; 2009 Jun; 86(3):176-203. PubMed ID: 19462404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digital pathology in drug discovery and development: multisite integration.
    Potts SJ
    Drug Discov Today; 2009 Oct; 14(19-20):935-41. PubMed ID: 19596461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Molecular and Immunohistochemical Adjunct Modalities in the Diagnosis of Soft Tissue Neoplasms.
    Mourtzoukou D; Fisher C; Thway K
    Int J Surg Pathol; 2015 Dec; 23(8):601-8. PubMed ID: 26310271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specimen collection and storage for diagnostic molecular pathology investigation.
    Farkas DH; Kaul KL; Wiedbrauk DL; Kiechle FL
    Arch Pathol Lab Med; 1996 Jun; 120(6):591-6. PubMed ID: 8651865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pathologist and toxicologist in pharmaceutical product discovery.
    Alden CL; Sagartz JE; Smith PF; Wilson AG; Bunch RT; Morris DL
    Toxicol Pathol; 1999; 27(1):104-6. PubMed ID: 10367682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative strategies for toxicity testing of species-specific biopharmaceuticals.
    Bussiere JL; Martin P; Horner M; Couch J; Flaherty M; Andrews L; Beyer J; Horvath C
    Int J Toxicol; 2009; 28(3):230-53. PubMed ID: 19546261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.